American Alpha Advisors LLC Invests $411,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• American Alpha Advisors LLC invested approximately $411,000 to acquire 3,664 shares of Gilead Sciences (NASDAQ:GILD) in the first quarter.
• Recent research reports have elevated analysts' ratings on Gilead, with Needham & Company moving the stock from a "hold" to a "buy" rating.
• The company has declared a quarterly dividend of $0.79, with an annualized dividend yield of 2.6%, to be paid on September 29th.

American Alpha Advisors LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 3,664 shares of the biopharmaceutical company's stock, valued at approximately $411,000.

A number of other large investors also recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter worth about $25,000. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences during the 1st quarter valued at $29,000. Core Alternative Capital increased its position in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the period. IMA Advisory Services Inc. bought a new stake in shares of Gilead Sciences during the 1st quarter worth $39,000. Finally, Clearstead Trust LLC boosted its stake in shares of Gilead Sciences by 287.6% during the 1st quarter. Clearstead Trust LLC now owns 376 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 279 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $0.45 during trading on Tuesday, reaching $120.02. The company had a trading volume of 6,084,059 shares, compared to its average volume of 6,236,199. Gilead Sciences, Inc. has a 12 month low of $72.67 and a 12 month high of $121.83. The stock has a market capitalization of $148.92 billion, a P/E ratio of 23.91, a price-to-earnings-growth ratio of 0.76 and a beta of 0.33. The company has a fifty day moving average of $111.16 and a two-hundred day moving average of $107.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.01 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the sale, the chief executive officer directly owned 615,725 shares in the company, valued at approximately $68,006,826.25. This trade represents a 1.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total transaction of $277,575.00. Following the sale, the chief financial officer owned 162,610 shares of the company's stock, valued at approximately $18,054,588.30. This represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $8,984,175 in the last quarter. 0.27% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Royal Bank Of Canada lifted their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday. Morgan Stanley boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. UBS Group upped their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday. Finally, Oppenheimer lowered their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Seven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $114.82.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.